Camille Salamand

501 total citations
8 papers, 382 citations indexed

About

Camille Salamand is a scholar working on Epidemiology, Immunology and Molecular Biology. According to data from OpenAlex, Camille Salamand has authored 8 papers receiving a total of 382 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Epidemiology, 5 papers in Immunology and 2 papers in Molecular Biology. Recurrent topics in Camille Salamand's work include Influenza Virus Research Studies (8 papers), Respiratory viral infections research (4 papers) and Immune Response and Inflammation (3 papers). Camille Salamand is often cited by papers focused on Influenza Virus Research Studies (8 papers), Respiratory viral infections research (4 papers) and Immune Response and Inflammation (3 papers). Camille Salamand collaborates with scholars based in France, United Kingdom and United States. Camille Salamand's co-authors include Stéphanie Pépin, Françoise Weber, Yves Donazzolo, Mélanie Saville, Geert Leroux‐Roels, Alen Jambrecina, Eva Vets, Isabel Leroux‐Roels, Michael Seiberling and Jiřı́ Beran and has published in prestigious journals such as Vaccine, BMC Medicine and Expert Review of Vaccines.

In The Last Decade

Camille Salamand

8 papers receiving 370 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Camille Salamand France	8	275	126	80	73	55	8	382
Jayesh Sanmukhani India	7	36 0.1×	76 0.6×	14 0.2×	215 2.9×	5 0.1×	10	319
Nawamin Pinpathomrat Thailand	9	88 0.3×	167 1.3×	9 0.1×	242 3.3×	6 0.1×	23	337
Ikbel Hadj Hassine Tunisia	5	41 0.1×	38 0.3×	5 0.1×	213 2.9×	10 0.2×	7	312
Suzanne Day United Kingdom	6	65 0.2×	79 0.6×	6 0.1×	42 0.6×	3 0.1×	7	226
Antonin Weckel United States	10	48 0.2×	93 0.7×	15 0.2×	80 1.1×	71 1.3×	14	266
Maja Jahnmatz Sweden	6	182 0.7×	85 0.7×	6 0.1×	66 0.9×		6	296
Vijayalakshmi Chandrasekaran United States	9	240 0.9×	72 0.6×	6 0.1×	76 1.0×	1 0.0×	22	300
Cyril Jean‐Marie Martel Denmark	8	126 0.5×	49 0.4×	4 0.1×	60 0.8×	1 0.0×	22	217
Eva van Doorn Netherlands	7	119 0.4×	119 0.9×	3 0.0×	43 0.6×	2 0.0×	11	244
Haode Huang Hong Kong	8	64 0.2×	147 1.2×	2 0.0×	460 6.3×	3 0.1×	9	555

Countries citing papers authored by Camille Salamand

Since Specialization

Citations

This map shows the geographic impact of Camille Salamand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Camille Salamand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Camille Salamand more than expected).

Fields of papers citing papers by Camille Salamand

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Camille Salamand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Camille Salamand. The network helps show where Camille Salamand may publish in the future.

Co-authorship network of co-authors of Camille Salamand

This figure shows the co-authorship network connecting the top 25 collaborators of Camille Salamand. A scholar is included among the top collaborators of Camille Salamand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Camille Salamand. Camille Salamand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Johansen, Niklas Dyrby, Daniel Modin, Joshua Nealon, et al.. (2023). A Pragmatic Randomized Feasibility Trial of Influenza Vaccines. NEJM Evidence. 2(2). EVIDoa2200206–EVIDoa2200206. 34 indexed citations

Johansen, Niklas Dyrby, Daniel Modin, Joshua Nealon, et al.. (2022). Feasibility of randomizing Danish citizens aged 65–79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 Trial. Pilot and Feasibility Studies. 8(1). 87–87. 16 indexed citations

Samson, Sandrine, Phillip S. Leventhal, Camille Salamand, et al.. (2019). Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis. Expert Review of Vaccines. 18(3). 295–308. 27 indexed citations

Sesay, Sanie, Jerzy Brzostek, Ingo Meyer, et al.. (2017). Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial. Human Vaccines & Immunotherapeutics. 14(3). 596–608. 17 indexed citations

Pépin, Stéphanie, Yves Donazzolo, Alen Jambrecina, Camille Salamand, & Mélanie Saville. (2013). Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine. 31(47). 5572–5578. 77 indexed citations

Beran, Jiřı́, Arvydas Ambrozaitis, Alvydas Pranas Laiškonis, et al.. (2009). Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Medicine. 7(1). 13–13. 82 indexed citations

Leroux‐Roels, Isabel, Eva Vets, Michael Seiberling, et al.. (2008). Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. Vaccine. 26(51). 6614–6619. 99 indexed citations

Salamand, Camille, et al.. (2005). Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip®. Vaccine. 24(10). 1586–1592. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact